McCarthy Sean A. 4
4 · CytomX Therapeutics, Inc. · Filed Feb 6, 2025
Insider Transaction Report
Form 4
McCarthy Sean A.
DirectorCEO
Transactions
- Award
Stock Option (Right to Buy)
2025-02-04+800,000→ 800,000 totalExercise: $0.86Exp: 2035-02-03→ Common Stock (800,000 underlying) - Award
Common Stock
2025-02-04+180,000→ 837,851 total - Award
Stock Option (Right to Buy)
2025-02-04+390,000→ 390,000 totalExercise: $0.86Exp: 2035-02-03→ Common Stock (390,000 underlying) - Award
Common Stock
2025-02-04+195,000→ 1,032,851 total
Holdings
- 93,158(indirect: See footnote)
Common Stock
Footnotes (6)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date.
- [F3]Includes 572,500 RSUs.
- [F4]Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
- [F5]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
- [F6]1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.